Jubilant Pharmova Limited
940.20
INR
+8.00
(+0.86%)
ISIN
INE700A01033
Return %
Stock
S&P 500
1Y
-16.58
14.39
3Y
162.26
81.42
5Y
55.61
68.62
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.Company Description
- CEO
- Priyavrat Bhartia
- Full Time Employees
- 6,386
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 1A, Sector 16A Noida UP India 201301
- IPO Date
- Nov 9, 1994
- Website
- jubilantpharmova.com
- Similar Companies
- Business
- Jubilant Pharmova Limited Jubilant Pharmova Limited is a global integrated pharmaceutical company focused on research, development, manufacturing, and distribution of specialty products across radiopharmaceuticals, allergy immunotherapy, sterile injectables contract development and manufacturing, generics, active pharmaceutical ingredients, and proprietary novel drugs. The company manufactures and supplies radiopharmaceuticals through a network of 46 radiopharmacies primarily in the US; provides over 200 allergenic extracts, venom products, and standard allergy vaccines for markets including the US, Canada, Europe, and Australia; offers contract manufacturing services for sterile fill-and-finish injectables including liquids, lyophilization, biologics, suspensions, ophthalmics, ointments, creams, ampoules, and non-sterile products at facilities in Spokane, Washington, and Montreal, Quebec; delivers contract research and development services via centers in Bengaluru, Noida, India, and Saint-Julien-en-Genevois, France, alongside active pharmaceutical ingredient production; develops generics in solid dosage forms; and advances proprietary novel drugs through Jubilant Therapeutics targeting oncology and autoimmune disorders such as essential thrombocythemia and non-small cell lung cancer. Operations span North America, Europe, India, and other regions with six manufacturing facilities serving regulated markets including the US, Europe, Canada, Japan, and Brazil; the company, founded in 1978 and headquartered in Noida, India, employs over 5,500 people worldwide. Recent developments include the launch of a third sterile fill-and-finish line at the Spokane facility with US$132 million investment, initiating revenue from technology transfers and positioning for full utilization within three years amid strong demand from large pharma for US-based capacity; a strategic partnership with Pierre Fabre SA via subsidiary Jubilant Biosys to acquire 80% of a new French entity incorporating its R&D center, enhancing biologics and antibody-drug conjugate capabilities; completion of the API business sale to Jubilant Biosys Limited for integrated CRDMO efficiency; commercial distribution of PYLARIFY from PET radiopharmacies; and progress in Phase II and Phase I clinical trials for JBI-802 and JBI-778, respectively.